New Zealand markets closed

Sarepta Therapeutics, Inc. (SRPT)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
68.71+1.41 (+2.10%)
At close: 04:00PM EST
69.00 +0.29 (+0.42%)
After hours: 06:56PM EST

Sarepta Therapeutics, Inc.

215 First Street
Suite 415
Cambridge, MA 02142
United States
617 274 4000

Full-time employees866

Key executives

NameTitlePayExercisedYear born
Mr. Douglas S. IngramPres, CEO & Director1.29MN/A1963
Mr. Ian Michael EstepanExec. VP & CFO684.12kN/A1976
Mr. William F. CiambroneExec. VP of Technical Operations679.94kN/A1964
Dr. Louise Rodino-Klapac Ph.D.Chief Scientific Officer and Head of R&D739.05kN/A1978
Dr. Gilmore O'Neill M.D.Exec. Officer891.94kN/A1965
Mr. Joseph BraticaController & VP438.51k2.07M1964
Mary JenkinsSr. Mang. of Investor RelationsN/AN/AN/A
Mr. Ryan E. BrownSr. VP, Gen. Counsel & Corp. Sec.N/AN/A1978
Ms. Alison NasisiChief People Officer & VPN/AN/AN/A
Dr. Diane L. BerrySr. VP of Global Health Policy and Gov. & Patient AffairsN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. The company offers EXONDYS 51 injection to treat duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping; and VYONDYS 53 for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. It also developing AMONDYS 45, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the dystrophin gene; SRP-5051, a peptide conjugated PMO that binds exon 51 of dystrophin pre-mRNA; SRP-9001, a DMD micro-dystrophin gene therapy program; and SRP-9003, a limb-girdle muscular dystrophies gene therapy program. The company has collaboration agreements with F. Hoffman-La Roche Ltd; Nationwide Children's Hospital; Lysogene; Duke University; Genethon; and StrideBio. It also has a research and option agreement with Codiak BioSciences, Inc. to design and develop engineered exosome therapeutics to deliver gene therapy, gene editing, and RNA technologies for neuromuscular diseases; and research collaboration with Genevant Sciences for lipid nanoparticle-based gene editing therapeutics. Sarepta Therapeutics, Inc. was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Corporate governance

Sarepta Therapeutics, Inc.’s ISS governance QualityScore as of 26 September 2021 is 3. The pillar scores are Audit: 3; Board: 3; Shareholder rights: 3; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.